# Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial

## TL;DR

A simple clinical score helps identify high-risk type 2 diabetes patients with increased cardiorenal risk, enabling early targeted interventions.

## Contribution

The study demonstrates the effectiveness of a previously developed risk score in stratifying cardiorenal risk in high-risk type 2 diabetes patients.

## Key findings

- The risk score showed strong, graded associations with cardiorenal outcomes across different risk groups.
- Higher-risk groups experienced earlier and more severe renal dysfunction and greater cardiovascular event risks.
- The score identified early renal function decline and elevated UACR, guiding timely interventions.

## Abstract

Early identification of patients with high cardiorenal risk and timely targeted interventions are critical in managing type 2 diabetes (T2D). Although we previously developed a multivariable risk score to predict diabetic kidney disease (DKD), its ability to stratify cardiorenal risk in T2D patients with established high cardiovascular risk remains unknown.

In this post-hoc analysis of the ELIXA trial, 2,635 T2D participants without baseline DKD were stratified into different risk groups (low-, moderate-, high-, and very high-risk group) using the previously developed risk score (incorporating nine simple clinical indicators: age, body mass index, hemoglobin A1c, systolic blood pressure, high-density lipoprotein cholesterol, triglycerides, smoking, diabetic retinopathy, and urinary albumin-to-creatinine ratio [UACR]). Patients were followed for renal outcomes (DKD incidence and progression) and cardiovascular outcomes (major adverse cardiovascular events [MACEs] and heart failure [HF]).

The risk score demonstrated strong, graded associations with cardiorenal outcomes. Over 108 weeks of renal follow-up, a progressive increase in DKD incidence was observed across risk strata (52.5% vs. 13.5% in the very high- vs. low-risk groups; relative risks [RR] 3.89, 95% confidence interval [CI] 2.82–5.38, P < 0.001). This graded pattern extended to other key events of renal disease progression: macroalbuminuria (5.1% vs. 0.8%; RR 9.37, 95% CI 2.41–36.46, P = 0.001), a ≥40% decline in estimated glomerular filtration rate (eGFR, 3.4% vs. 0.2%; RR 17.72, 95% CI 1.58–198.82, P = 0.020), and rapid renal function decline (44.2% vs. 29.5%; RR 1.89, 95% CI 1.06–3.37; P = 0.032). Higher-risk groups exhibited earlier and progressively worsening renal dysfunction, with eGFR decline evident as early as week 24 and UACR elevation becoming significant by week 76, both persisting through week 108. During the 224-week cardiovascular follow-up, the combined high/very high-risk group had significantly greater risks of both MACEs (15.2% vs. 6.8%; hazard ratio [HR] 1.86, 95% CI 1.26–2.74, P = 0.001) and HF (2.8% vs. 0.5%; HR 4.58, 95% CI 1.41–14.9, P = 0.011) compared to the low-risk group.

This practical risk score identifies high-risk T2D patients with cardiorenal risk, including early renal function decline, to guide targeted intervention.